Development asset linked to SAB Biotherapeutics in public FDA and regional records. Molecular target: Spike glycoprotein.
- Target
- Spike glycoprotein
- Mechanism
- Spike glycoprotein inhibitor
biotech · Type 1 Diabetes · Coronavirus · SABS
SAB Biotherapeutics
SAB Biotherapeutics drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Gaithersburg, USA HQ
2016 Founded
39 Employees
Public company Type
SABS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Gaithersburg, USA
- Founded
- 2016
- Employees
- 39
- Programs
- 8
- Drugs
- 10
- Patents
- 1
SAB Biotherapeutics pipeline
Portfolio lens on 10 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
SAB Biotherapeutics drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to SAB Biotherapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
Development asset linked to SAB Biotherapeutics in public FDA and regional records.
-
Development asset linked to SAB Biotherapeutics in public FDA and regional records.
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in SAB Biotherapeutics's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to SAB Biotherapeutics in public FDA and regional records.
-
Development asset linked to SAB Biotherapeutics in public FDA and regional records.
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in SAB Biotherapeutics's portfolio.
-
US regulatory status: approved.